Rivastigmine
Active pharmaceutical substance formulated in Jan Aushadhi generic products for CNS, Nerve & Mental Health treatment.
🧴 Clinical Application
Take orally twice daily with meals (morning and evening) with water to reduce cholinergic gastrointestinal adverse effects. Titrate slowly over several weeks.
⚠️ Side Effects
Common: Nausea, vomiting, anorexia, dyspepsia, weight loss, diarrhea, dizziness, headache. Rare/Severe: Severe vomiting with esophageal rupture, bradycardia, syncope, and peptic ulceration.
🛡️ Safety Warnings
Transdermal patch reduces gastrointestinal side effects compared to oral capsules; ensure only one patch is worn at a time to prevent life-threatening cholinergic overdose. Vagotonic effects can cause bradycardia. Caution in asthma, COPD, and peptic ulcer disease.
Jan Aushadhi Products containing Rivastigmine
Found 7 generic formulation(s) containing this active ingredient.
Rivastigmine Capsules 1.5mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Capsules 3mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Capsules 4.5 mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Capsules 6 mg
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Transdermal Patch 9mg (4.6mg/24 hour)
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Transdermal Patch 18mg (9.5mg/24 hour)
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Rivastigmine Transdermal Patch 27mg (13.3mg/24 hour)
Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Rivastigmine.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Rivastigmine Capsules 1.5mg | 10's | ₹46.88 | RIVAMER, RIFANIA, RIVAZIN, VEROLIN | ₹196.97 | 76% Save |
| Rivastigmine Capsules 3mg | 10's | Under Process | N/A | N/A | N/A |
| Rivastigmine Capsules 4.5 mg | 10's | Under Process | N/A | N/A | N/A |
| Rivastigmine Capsules 6 mg | 10's | Under Process | N/A | N/A | N/A |
| Rivastigmine Transdermal Patch 9mg (4.6mg/24 hour) | 30's in monocarton | Under Process | N/A | N/A | N/A |
| Rivastigmine Transdermal Patch 18mg (9.5mg/24 hour) | 30's in monocarton | Under Process | N/A | N/A | N/A |
| Rivastigmine Transdermal Patch 27mg (13.3mg/24 hour) | 30's in monocarton | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Rivastigmine generics.